UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 30

of 'Intestinal Entamoeba histolytica amebiasis'

30
TI
Further diagnostic use of an invasive-specific monoclonal antibody against Entamoeba histolytica.
AU
González-Ruíz A, Haque R, Rehman T, Aguirre A, Castañón G, Hall A, Guhl F, Ruíz-Palacios G, Warhurst DC, Miles MA
SO
Arch Med Res. 1992;23(2):281.
 
Genotypic differences between invasive and non-invasive E. histolytica could explain the 1:10 ratio of symptomatic/asymptomatic infection worldwide. Currently, zymodeme analysis is used to differentiate invasive from non-invasive E. histolytica strains but the technique is cumbersome and expensive. In accordance with the WHO research priorities for amebiasis we report here the further use of an invasive-specific monoclonal antibody against E. histolytica in immunofluorescence, to identify isolates cultured from stool samples of patients from three geographically distant endemic regions: Bangladesh, Colombia and Mexico. We tested 107 E. histolytica isolates and the correlation between zymodeme characterization and the immunofluorescence assay was 100%.
AD
Department of Medical Parasitology, London School of Hygiene and Tropical Medicine, UK.
PMID